383 - Polysubstance Use in Patients Prescribed Medications for Opioid Use Disorder: Current Evidence from Urine Drug Testing to Inform Treatment Planning

Session Description: Drug overdose deaths are higher than ever, and more overdose deaths co-involve illicit fentanyl than any other drug alone. Addiction professionals must maintain awareness of current trends in illicit drug use and how they may affect clinical practice. While medications for opioid use disorder (MOUD) can reduce harmful opioid use, concurrent use of other non-prescribed off illicit substances may negatively affect treatment outcomes. Urine drug testing (UDT) provides clinically-actionable. objective information about poly-substance use to support clinical decision making. This workshop will provide insight into current drug use trends, with an emphasis on poly-substance use, from a database of millions of definitive UDT results. It will also describe non-prescribed and illicit drug use among patients who are prescribed buprenorphine or methadone and how drug use may differ based on whether patients are taking their prescribed MOUD. Key considerations for monitoring medications in this patient population will be discussed in the context of a comprehensive treatment approach. A case-based approach will be used to facilitate the development of skills to identify and navigate scenarios involving poly-substance use in clinical practice to improve treatment planning and patient care.